[go: up one dir, main page]

MX2022010490A - Composiciones utiles para enzimas de internalizacion. - Google Patents

Composiciones utiles para enzimas de internalizacion.

Info

Publication number
MX2022010490A
MX2022010490A MX2022010490A MX2022010490A MX2022010490A MX 2022010490 A MX2022010490 A MX 2022010490A MX 2022010490 A MX2022010490 A MX 2022010490A MX 2022010490 A MX2022010490 A MX 2022010490A MX 2022010490 A MX2022010490 A MX 2022010490A
Authority
MX
Mexico
Prior art keywords
compositions
methods
internalizing
enzymes
biotherapeutic
Prior art date
Application number
MX2022010490A
Other languages
English (en)
Inventor
Katherine Cygnar
Andrew Baik
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2022010490A publication Critical patent/MX2022010490A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6815—Enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2434—Glucanases acting on beta-1,4-glucosidic bonds
    • C12N9/2445—Beta-glucosidase (3.2.1.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04041—Sphingomyelin phosphodiesterase D (3.1.4.41)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0102—Alpha-glucosidase (3.2.1.20)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01021—Beta-glucosidase (3.2.1.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01022—Alpha-galactosidase (3.2.1.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01023—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01031—Beta-glucuronidase (3.2.1.31)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01076—L-Iduronidase (3.2.1.76)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/06—Fusion polypeptide containing a localisation/targetting motif containing a lysosomal/endosomal localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Las enzimas de reemplazo pueden suministrarse eficazmente al lisosoma de una cĆ©lula diana especĆ­fica cuando se asocian con una entidad de direccionamiento a la superficie celular. La presente invenciĆ³n proporciona una combinaciĆ³n de la enzima y la entidad de direccionamiento que se denomina complejo bioterapĆ©utico. Por tanto, se proporciona una composiciĆ³n, es decir, un complejo bioterapĆ©utico que comprende una enzima y una proteĆ­na de uniĆ³n a antĆ­geno. La enzima estĆ” asociada con una enfermedad de almacenamiento lisosomal (LSD) y la proteĆ­na de uniĆ³n a antĆ­geno se une a un efector de internalizaciĆ³n. El efector de internalizaciĆ³n media la uniĆ³n celular y la captaciĆ³n a un compartimento lisosĆ³mico. Los complejos bioterapĆ©uticos son capaces de ingresar a las cĆ©lulas, segregarse en el lisosoma y suministrar la actividad enzimĆ”tica de reemplazo al lisosoma que reemplaza la actividad enzimĆ”tica asociada con la LSD ("enzima endĆ³gena") y una proteĆ­na de uniĆ³n a antĆ­geno que se une a un efector de internalizaciĆ³n, en donde el efector de internalizaciĆ³n es CD63.
MX2022010490A 2015-12-08 2018-06-08 Composiciones utiles para enzimas de internalizacion. MX2022010490A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562264702P 2015-12-08 2015-12-08
US201662379629P 2016-08-25 2016-08-25

Publications (1)

Publication Number Publication Date
MX2022010490A true MX2022010490A (es) 2022-09-21

Family

ID=57868326

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2018007061A MX2018007061A (es) 2015-12-08 2016-12-08 Composiciones y metodos para enzimas de internalizacion.
MX2022010490A MX2022010490A (es) 2015-12-08 2018-06-08 Composiciones utiles para enzimas de internalizacion.
MX2023000731A MX2023000731A (es) 2015-12-08 2018-06-08 Composiciones utiles para enzimas de internalizacion.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018007061A MX2018007061A (es) 2015-12-08 2016-12-08 Composiciones y metodos para enzimas de internalizacion.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023000731A MX2023000731A (es) 2015-12-08 2018-06-08 Composiciones utiles para enzimas de internalizacion.

Country Status (23)

Country Link
US (2) US20190112588A1 (es)
EP (3) EP3386534B1 (es)
JP (3) JP7065770B2 (es)
KR (2) KR102851747B1 (es)
CN (2) CN108367056B (es)
AU (2) AU2016365834B2 (es)
BR (1) BR112018011474A2 (es)
CA (1) CA3006460A1 (es)
CY (1) CY1123676T1 (es)
DK (3) DK3782639T3 (es)
EA (1) EA201891277A1 (es)
ES (3) ES2926280T3 (es)
FI (1) FI4074331T3 (es)
HU (2) HUE052155T2 (es)
IL (3) IL287019B2 (es)
MX (3) MX2018007061A (es)
MY (2) MY207684A (es)
NZ (2) NZ783252A (es)
PH (1) PH12018501074A1 (es)
PL (2) PL3782639T3 (es)
PT (3) PT4074331T (es)
SG (1) SG11201804375WA (es)
WO (1) WO2017100467A2 (es)

Families Citing this family (45)

* Cited by examiner, ā€  Cited by third party
Publication number Priority date Publication date Assignee Title
PL2825553T3 (pl) 2012-03-14 2018-12-31 Regeneron Pharmaceuticals, Inc. Wieloswoiste cząsteczki wiążące antygen i ich zastosowanie
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
CA2987641A1 (en) 2015-07-06 2017-01-12 Regeneron Pharmaceuticals, Inc. Multispecific antigen-binding molecules and uses thereof
KR102851747B1 (ko) * 2015-12-08 2025-08-28 ė¦¬ģ œė„ˆė”  ķŒŒė§ˆģŠˆķ‹°ģ¹¼ģŠ¤ ģøģ½”ķ¬ė ˆģ“ķ‹°ė“œ ķšØģ†Œ ė‚“ģž¬ķ™” ģ”°ģ„±ė¬¼ ė° ė°©ė²•
CA3049661A1 (en) 2017-01-11 2018-07-19 The Board Of Trustees Of The Leland Stanford Junior University R-spondin (rspo) surrogate molecules
CN110234662A (zh) 2017-01-26 2019-09-13 ē‘Ÿē½—ę³½ę©å…¬åø ē»„ē»‡ē‰¹å¼‚ꀧwntäæ”号增å¼ŗ分子和其ē”Ø途
BR112019025888A2 (pt) 2017-06-07 2020-06-30 Regeneron Pharmaceuticals, Inc. polinucleotĆ­deo que codifica uma proteĆ­na terapĆŖutica multidomĆ­nio, vetor de terapia gĆŖnica, proteĆ­na terapĆŖutica multidomĆ­nio recombinante, mĆ©todo de expressĆ£o, mĆ©todos para reduzir o acĆŗmulo de glicogĆŖnio em um tecido em um paciente em necessidade, para reduzir o acĆŗmulo de glicogĆŖnio em um tecido em um paciente em necessidade epara tratar a deficiĆŖncia enzimĆ”tica em um paciente em necessidade e/ou tolerar o paciente Ć  enzima para a qual Ć© deficiente, anticorpo anti-cd63 ou fragmento de ligaĆ§Ć£o a antĆ­geno, e, composiĆ§Ć£o farmacĆŖutica
IL271561B2 (en) 2017-06-27 2025-08-01 Regeneron Pharma Non-human animals comprising a humanized asgr1 locus
BR112020000273A2 (pt) * 2017-07-07 2020-07-14 Hanmi Pharm. Co., Ltd. proteĆ­na de fusĆ£o de enzima e seu mĆ©todo de preparaĆ§Ć£o, composiĆ§Ć£o farmacĆŖutica, polinucleotĆ­deo que codifica a proteĆ­na de fusĆ£o de enzima, vetor de expressĆ£o, transformante
CA3076369A1 (en) 2017-10-02 2019-04-11 Denali Therapeutics Inc. Fusion proteins comprising enzyme replacement therapy enzymes
EP3708661A4 (en) 2017-12-22 2021-12-01 Hanmi Pharm. Co., Ltd. THERAPEUTIC ENZYMFUSION PROTEIN WITH A NEW STRUCTURE AND ITS USE
US20210038739A1 (en) * 2018-02-05 2021-02-11 Jcr Pharmaceuticals Co., Ltd. Method for Delivering Drug to Muscle
JP7779653B2 (ja) * 2018-02-07 2025-12-03 ćƒŖć‚øć‚§ćƒćƒ­ćƒ³ćƒ»ćƒ•ć‚”ćƒ¼ćƒžć‚·ćƒ„ćƒ¼ćƒ†ć‚£ć‚«ćƒ«ć‚ŗćƒ»ć‚¤ćƒ³ć‚³ćƒ¼ćƒćƒ¬ć‚¤ćƒ†ćƒƒćƒ‰ ę²»ē™‚ē”Øć‚æćƒ³ćƒ‘ć‚Æč³Ŗé€é”ć®ćŸć‚ć®ę–¹ę³•ćŠć‚ˆć³ēµ„ęˆē‰©
MY206284A (en) 2018-05-17 2024-12-06 Regeneron Pharma Anti-cd63 antibodies, conjugates, and uses thereof
EP3820499A4 (en) 2018-07-09 2022-07-13 Surrozen Operating, Inc. TISSUE SPECIFIC WNT SIGNAL ENHANCEMENT MOLECULES AND USES
US11911484B2 (en) 2018-08-02 2024-02-27 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US12370264B1 (en) 2018-08-02 2025-07-29 Dyne Therapeutics, Inc. Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
US20220193250A1 (en) 2018-08-02 2022-06-23 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
KR20210054513A (ko) * 2018-08-02 2021-05-13 ė‹¤ģø ģ„øė¼ķ“Øķ‹±ģŠ¤, ģøķ¬. ź·¼ģœ” ķ‘œģ ķ™” ė³µķ•©ģ²“ ė° ķ¼ķŽ˜ė³‘ģ„ ģ¹˜ė£Œķ•˜źø° ģœ„ķ•œ ź·øģ˜ ģš©ė„
US12097263B2 (en) 2018-08-02 2024-09-24 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
EP3830130A4 (en) * 2018-08-02 2022-05-18 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating centronuclear myopathy
WO2020028832A1 (en) 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
CN113301925A (zh) 2018-12-19 2021-08-24 小利兰Ā·ę–Æ坦ē¦å¤§å­¦ē†äŗ‹ä¼š ē”ØäŗŽęŗ¶é…¶ä½“靶向ēš„åŒå®˜čƒ½åˆ†å­ä»„及ē›ø关ēš„ē»„合ē‰©å’Œę–¹ę³•
CA3145672A1 (en) * 2019-07-03 2021-01-07 Palleon Pharmaceuticals Inc. Sialidase-cd20-antibody fusion proteins and methods of use thereof
MA71661A (fr) 2020-10-14 2025-05-30 Denali Therapeutics Inc. ProtƩines de fusion comprenant des enzymes sulfoglucosamine sulfohydrolase et mƩthodes associƩes
TW202233656A (zh) 2020-11-16 2022-09-01 ē¾Žå•†č˜‡ē¾…ę£®ē‡Ÿé‹å…¬åø 肝ē‰¹ē•°ę€§wntčØŠč™Ÿå¢žå¼·åˆ†å­åŠå…¶ē”Ø途
EP4366784A1 (en) 2021-07-09 2024-05-15 Dyne Therapeutics, Inc. Muscle targeting complexes and formulations for treating dystrophinopathies
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11633498B2 (en) 2021-07-09 2023-04-25 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US11672872B2 (en) 2021-07-09 2023-06-13 Dyne Therapeutics, Inc. Anti-transferrin receptor antibody and uses thereof
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
JP2024524614A (ja) 2021-07-14 2024-07-05 ćƒ©ć‚¤ć‚·ć‚¢ ć‚»ćƒ©ćƒ”ćƒ„ćƒ¼ćƒ†ć‚£ć‚Æć‚¹ļ¼Œ ć‚¤ćƒ³ć‚³ćƒ¼ćƒćƒ¬ć‚¤ćƒ†ćƒƒćƒ‰ ļ¼”ļ½“ļ½‡ļ½ļ½’ē“°čƒžč”Ø面受容体ēµåˆåŒ–合ē‰©åŠć³ć‚³ćƒ³ć‚øćƒ„ć‚²ćƒ¼ćƒˆ
WO2023016828A2 (en) * 2021-07-30 2023-02-16 Vib Vzw Cation-independent mannose-6-phosphate receptor binders for targeted protein degradation
EP4473103A2 (en) 2022-02-02 2024-12-11 Regeneron Pharmaceuticals, Inc. Anti-tfr:gaa and anti-cd63:gaa insertions for treatment of pompe disease
AU2023254846A1 (en) 2022-04-15 2024-10-10 Dyne Therapeutics, Inc. Muscle targeting complexes and formulations for treating myotonic dystrophy
US20240182561A1 (en) * 2022-11-04 2024-06-06 Regeneron Pharmaceuticals, Inc. Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle
JP2025538220A (ja) 2022-11-14 2025-11-26 ćƒŖć‚øć‚§ćƒćƒ­ćƒ³ćƒ»ćƒ•ć‚”ćƒ¼ćƒžć‚·ćƒ„ćƒ¼ćƒ†ć‚£ć‚«ćƒ«ć‚ŗćƒ»ć‚¤ćƒ³ć‚³ćƒ¼ćƒćƒ¬ć‚¤ćƒ†ćƒƒćƒ‰ ć‚¢ć‚¹ćƒˆćƒ­ć‚µć‚¤ćƒˆćø恮ē·šē¶­čŠ½ē“°čƒžå¢—ę®–å› å­å—å®¹ä½“ļ¼“åŖ’ä»‹é€é”ć®ćŸć‚ć®ēµ„ęˆē‰©ćŠć‚ˆć³ę–¹ę³•
WO2025029654A2 (en) 2023-07-28 2025-02-06 Regeneron Pharmaceuticals, Inc. Use of bgh-sv40l tandem polya to enhance transgene expression during unidirectional gene insertion
WO2025029657A2 (en) 2023-07-28 2025-02-06 Regeneron Pharmaceuticals, Inc. Anti-tfr:gaa and anti-cd63:gaa insertion for treatment of pompe disease
WO2025137213A1 (en) 2023-12-20 2025-06-26 Denali Therapeutics Inc. Fusion proteins comprising acid alpha-glucosidase enzymes and methods thereof
US20250242056A1 (en) 2024-01-26 2025-07-31 Regeneron Pharmaceuticals, Inc. Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing
WO2025184567A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response

Family Cites Families (20)

* Cited by examiner, ā€  Cited by third party
Publication number Priority date Publication date Assignee Title
EP2399586A1 (en) * 2002-01-11 2011-12-28 Jefferies, Dr., Wilfred Use of P97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes
US20050142141A1 (en) * 2002-11-27 2005-06-30 Pardridge William M. Delivery of enzymes to the brain
WO2006108052A2 (en) * 2005-04-06 2006-10-12 Genzyme Corporation Peg and polysialic lysosomal enzyme conjugates via acid labile linkers for therapeutic targeting
EP1981546B1 (en) * 2006-02-06 2014-06-04 The Medical Research and Infrastructure Fund of the Tel-Aviv Sourasky Medical Center Enzyme replacement therapy for treating lysosomal storage diseases
US8569032B2 (en) * 2007-05-18 2013-10-29 Tokyo Metropolitan Institute Of Medical Science Proteins having acquired A-galactosidase activity
JP6151183B2 (ja) * 2010-09-29 2017-06-21 ć‚Ŗć‚­ć‚·ćƒ¬ć‚¤ćƒ³ ćƒ¦ćƒ¼ć‚±ćƒ¼ ćƒŖ惟惆惃惉 ćƒžćƒ³ćƒŽćƒ¼ć‚¹āˆ’ļ¼‘āˆ’ćƒ›ć‚¹ćƒ›āˆ’ļ¼–āˆ’ćƒžćƒ³ćƒŽćƒ¼ć‚¹ēµåˆć‹ć‚‰ć‚­ćƒ£ćƒƒćƒ—ć‚’å¤–ć™ć“ćØćŠć‚ˆć³ćƒŖćƒ³é…ø化ļ½Žāˆ’ć‚°ćƒŖć‚«ćƒ³ć‚’č„±ćƒžćƒ³ćƒŽć‚·ćƒ«åŒ–ć™ć‚‹ć“ćØćŒć§ćć‚‹ćƒžćƒ³ćƒŽć‚·ćƒ€ćƒ¼ć‚¼ćŖć‚‰ć³ć«å“ŗ乳動ē‰©ē“°čƒžć«ć‚ˆć‚‹ē³–ć‚æćƒ³ćƒ‘ć‚Æč³Ŗć®å–ć‚Šč¾¼ćæ悒äæƒé€²ć™ć‚‹ę–¹ę³•
CA2836318C (en) * 2011-05-27 2018-11-27 Callidus Biopharma, Inc. Methods for coupling targeting peptides onto recombinant lysosomal enzymes for improved treatments of lysosomal storage diseases
DK2739649T3 (en) * 2011-08-05 2018-01-08 Bioasis Technologies Inc P97 FRAGMENTS WITH TRANSFER ACTIVITY
PL2663575T3 (pl) 2011-10-28 2015-03-31 Regeneron Pharma Humanizowane IL-6 i receptor IL-6
PL2825553T3 (pl) * 2012-03-14 2018-12-31 Regeneron Pharmaceuticals, Inc. Wieloswoiste cząsteczki wiążące antygen i ich zastosowanie
HUE045144T2 (hu) * 2012-08-29 2019-12-30 Hoffmann La Roche VƩragygƔt-shuttle
AU2014218854B2 (en) * 2013-02-20 2019-01-24 Valerion Therapeutics, Llc Methods and compositions for treatment of Pompe disease
TWI641620B (zh) 2013-08-21 2018-11-21 再ē”Ÿå…ƒé†«č—„公åø ꊗļ¼ļ½ļ½’ļ½Œļ½’ęŠ—é«”åŠå…¶ē”Ø途
CA2962081A1 (en) * 2014-09-26 2016-03-31 Exerkine Corporation Exosomes useful to treat lysosomal storage disease
EP3220958A1 (en) * 2014-10-24 2017-09-27 Shire Human Genetic Therapies, Inc. Lysosomal targeting of enzymes, and uses thereof
MA41022A (fr) * 2014-11-24 2017-10-03 Shire Human Genetic Therapies Ciblage lysosomial et utilisations correspondantes
TWI769982B (zh) * 2015-06-24 2022-07-11 ę—„å•†ļ¼Ŗļ½ƒļ½’č£½č—„č‚”ä»½ęœ‰é™å…¬åø é€šéŽč”€č…¦éšœå£ä¹‹ęŠ—äŗŗ锞運鐵蛋ē™½å—體ꊗ體
KR102851747B1 (ko) * 2015-12-08 2025-08-28 ė¦¬ģ œė„ˆė”  ķŒŒė§ˆģŠˆķ‹°ģ¹¼ģŠ¤ ģøģ½”ķ¬ė ˆģ“ķ‹°ė“œ ķšØģ†Œ ė‚“ģž¬ķ™” ģ”°ģ„±ė¬¼ ė° ė°©ė²•
BR112019025888A2 (pt) * 2017-06-07 2020-06-30 Regeneron Pharmaceuticals, Inc. polinucleotĆ­deo que codifica uma proteĆ­na terapĆŖutica multidomĆ­nio, vetor de terapia gĆŖnica, proteĆ­na terapĆŖutica multidomĆ­nio recombinante, mĆ©todo de expressĆ£o, mĆ©todos para reduzir o acĆŗmulo de glicogĆŖnio em um tecido em um paciente em necessidade, para reduzir o acĆŗmulo de glicogĆŖnio em um tecido em um paciente em necessidade epara tratar a deficiĆŖncia enzimĆ”tica em um paciente em necessidade e/ou tolerar o paciente Ć  enzima para a qual Ć© deficiente, anticorpo anti-cd63 ou fragmento de ligaĆ§Ć£o a antĆ­geno, e, composiĆ§Ć£o farmacĆŖutica
JP7779653B2 (ja) * 2018-02-07 2025-12-03 ćƒŖć‚øć‚§ćƒćƒ­ćƒ³ćƒ»ćƒ•ć‚”ćƒ¼ćƒžć‚·ćƒ„ćƒ¼ćƒ†ć‚£ć‚«ćƒ«ć‚ŗćƒ»ć‚¤ćƒ³ć‚³ćƒ¼ćƒćƒ¬ć‚¤ćƒ†ćƒƒćƒ‰ ę²»ē™‚ē”Øć‚æćƒ³ćƒ‘ć‚Æč³Ŗé€é”ć®ćŸć‚ć®ę–¹ę³•ćŠć‚ˆć³ēµ„ęˆē‰©

Also Published As

Publication number Publication date
WO2017100467A4 (en) 2017-09-21
EP3782639A1 (en) 2021-02-24
IL287019A (en) 2021-12-01
IL320861A (en) 2025-07-01
DK3782639T3 (da) 2022-08-29
WO2017100467A2 (en) 2017-06-15
KR20180084895A (ko) 2018-07-25
PT3782639T (pt) 2022-08-10
CY1123676T1 (el) 2022-03-24
SG11201804375WA (en) 2018-06-28
EA201891277A1 (ru) 2018-11-30
PT3386534T (pt) 2020-11-24
US20190112588A1 (en) 2019-04-18
ES3045508T3 (en) 2025-11-28
AU2023285891A1 (en) 2024-01-18
AU2023285891B2 (en) 2024-10-03
JP2024116182A (ja) 2024-08-27
CA3006460A1 (en) 2017-06-15
NZ783252A (en) 2024-12-20
MX2018007061A (es) 2018-08-15
MY187933A (en) 2021-10-29
AU2016365834B2 (en) 2023-09-28
EP4074331B1 (en) 2025-09-03
WO2017100467A3 (en) 2017-07-20
AU2024278420A1 (en) 2025-01-09
HUE052155T2 (hu) 2021-04-28
NZ743008A (en) 2023-05-26
JP7524236B2 (ja) 2024-07-29
CN116196400A (zh) 2023-06-02
JP7065770B2 (ja) 2022-05-12
IL287019B1 (en) 2025-06-01
EP3386534A2 (en) 2018-10-17
ES2926280T3 (es) 2022-10-25
PH12018501074A1 (en) 2019-01-28
DK4074331T3 (da) 2025-10-20
NZ783256A (en) 2025-05-02
ES2833937T3 (es) 2021-06-16
AU2016365834A1 (en) 2018-06-21
PL3782639T3 (pl) 2022-11-28
MX2023000731A (es) 2023-02-13
MY207684A (en) 2025-03-12
HUE060136T2 (hu) 2023-02-28
FI4074331T3 (fi) 2025-10-22
JP2019505480A (ja) 2019-02-28
DK3386534T3 (da) 2020-11-30
IL259714A (en) 2018-07-31
US20250188433A1 (en) 2025-06-12
EP4074331A1 (en) 2022-10-19
PT4074331T (pt) 2025-11-04
IL287019B2 (en) 2025-10-01
BR112018011474A2 (en) 2018-12-04
CN108367056A (zh) 2018-08-03
CN108367056B (zh) 2022-12-23
PL3386534T3 (pl) 2021-03-08
EP3386534B1 (en) 2020-09-23
KR20250133801A (ko) 2025-09-08
EP3782639B1 (en) 2022-07-20
JP2022058799A (ja) 2022-04-12
KR102851747B1 (ko) 2025-08-28

Similar Documents

Publication Publication Date Title
MX2022010490A (es) Composiciones utiles para enzimas de internalizacion.
PH12019550261A1 (en) Compositions and methods for internalizing enzymes
PH12020550510A1 (en) Fusion proteins comprising enzyme replacement therapy enzymes
MX2017004691A (es) Bloqueo de cd73.
EP4559918A3 (en) Glucosylceramide synthase inhibitors
PH12018500810A1 (en) Antibody agents specific for human cd19 and uses thereof
MX2018014890A (es) Composiciones de limpieza que comprenden enzimas.
MX2019007143A (es) Procesamiento de materiales de biomasa.
AU2015311681A8 (en) Globin gene therapy for treating hemoglobinopathies
EP2596122A4 (en) MODULATORS OF SIRT5 AND TESTS FOR SCREENING
MX2019009229A (es) Novedosas variantes enzimaticas que degradan la nicotina.
MX2018010196A (es) Proteinas de fusion de enzimas lisosomales terapeuticas dirigidas, formulaciones asociadas y usos de las mismas.
SG10201804952QA (en) Glucosylceramide synthase inhibitors
MX2015012842A (es) Prodecimiento para preparar inhibidores de la glucosilceramida sintasa.
CA2986376C (en) Poxvirus-derived promoter, and vector comprising same
MX2015009949A (es) Supresor de mimicos de lesion 1 (slm1) suspresor de fenotipos mimicos de lesion.
MX2016008716A (es) Expresion aumentada de proteinas.
MX2017014828A (es) Procesos para incrementar la extraccion de enzimas de alimento animal y medir la actividad de las mismas.
MX2016008595A (es) Expresion mejorada de proteĆ­nas.
TN2013000368A1 (en) Glucosylceramide synthase inhibitors